UCLB logo

UCLB

Europe, England, United Kingdom, London

Description

UCL Business PLC (UCLB) is the dedicated commercialisation company for University College London (UCL), a globally renowned research institution. As a wholly owned subsidiary, UCLB plays a pivotal role in translating UCL's world-leading research and intellectual property into tangible societal and economic impact. Its core mission is to bridge the gap between academic innovation and market application, fostering the creation of new ventures and licensing groundbreaking technologies. UCLB's strategic importance lies in enabling UCL to fulfill its third core mission, focusing on real-world impact beyond traditional academic pursuits.

UCLB primarily focuses its investment activities on UCL spinout companies, typically engaging at the crucial seed and Series A stages. The firm's investment strategy is deeply rooted in supporting technologies that demonstrate significant potential for both societal benefit and economic growth. While UCLB provides critical early-stage capital, it frequently co-invests alongside a diverse range of external partners, including other venture capital firms, corporate investors, and angel investors. This collaborative approach ensures that its portfolio companies receive robust financial backing and strategic support beyond UCLB's initial commitment.

The typical initial investment from UCLB ranges from £50,000 to £2 million, with the flexibility to provide follow-on funding as companies mature and achieve milestones. This financial commitment is complemented by extensive support in business development, intellectual property management, and strategic guidance. Since 2004, UCLB has been instrumental in the formation of over 100 spinout companies, showcasing its consistent ability to nurture innovative ventures from inception. Furthermore, these UCLB-backed spinouts have collectively attracted over £3 billion in external investment, underscoring the high quality and market appeal of the technologies emerging from UCL's research ecosystem.

Investor Profile

UCLB has backed more than 39 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 11 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Seed, Series A, Series Unknown rounds (top funding stages).
  • Majority of deals are located in United Kingdom.
  • Strong thematic focus on Health Care, Biotechnology, Medical.
  • Typical check size: $63.5K – $2.5M.

Stage Focus

  • Seed (69%)
  • Series A (8%)
  • Series Unknown (8%)
  • Series B (5%)
  • Series C (3%)
  • Grant (3%)
  • Angel (3%)
  • Pre Seed (3%)

Country Focus

  • United Kingdom (100%)

Industry Focus

  • Health Care
  • Biotechnology
  • Medical
  • Software
  • Pharmaceutical
  • Medical Device
  • Therapeutics
  • Machine Learning
  • Manufacturing
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does UCLB frequently co-invest with?

CA
North America, Massachusetts, United States, Boston
Co-Investments: 1
AlbionVC
Europe, England, United Kingdom, London
Co-Investments: 4
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 1
UCL Technology Fund
Europe, England, United Kingdom, London
Co-Investments: 3
Imperial Innovations
Europe, England, United Kingdom, London
Co-Investments: 3
Arix Bioscience
Europe, England, United Kingdom, London
Co-Investments: 1
London Co-Investment Fund
Europe, England, United Kingdom, London
Co-Investments: 2
AI Seed
Europe, England, United Kingdom, London
Co-Investments: 2
Syncona Partners LLP
Europe, England, United Kingdom, London
Co-Investments: 2
Wellcome Trust
Europe, England, United Kingdom, London
Co-Investments: 2

What are some of recent deals done by UCLB?

Carbon Re

London, England, United Kingdom

Carbon Re is a climate technology company developing artificial intelligence to decarbonize energy-intensive industries.

Artificial Intelligence (AI)Machine LearningManufacturingSoftware
Pre SeedOct 20, 2021
Amount Raised: $1,402,934
Astroscreen

London, England, United Kingdom

Astroscreen protects brands and defends democracy from harmful social media manipulation campaigns also known as astroturfing.

Information Technology
SeedApr 18, 2019
Amount Raised: $1,000,000
Hazy

London, England, United Kingdom

Hazy is the world’s leading synthetic data company, re-engineering enterprise data so that it’s faster, easier and safer to use.

Enterprise SoftwareMachine LearningSoftware
SeedMay 2, 2018
Amount Raised: $1,800,000
Intrinsic Semiconductor Technologies

London, England, United Kingdom

Intrinsic Semiconductor Technologies is established to developed silicon-oxide based RRAM technologies.

Artificial Intelligence (AI)ElectronicsInformation TechnologyManufacturingSemiconductor
SeedJan 1, 2018
Correvate

London, England, United Kingdom

Correvate was formed to commercialise point cloud processing technology (Vercator) that emerged from UCL.

3D TechnologyBig DataCivil EngineeringCloud ComputingCloud Data ServicesComputerComputer VisionConstructionGeospatial
SeedJan 1, 2018
Autolus

London, England, United Kingdom

Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.

BiopharmaBiotechnologyMedicalPharmaceutical
Series CSep 26, 2017
Amount Raised: $80,000,000
Appredict

London, England, United Kingdom

Appredict is a data analysis company that specialises in analysing and understanding the development lifecycle of apps.

AnalyticsData StorageSoftware
SeedJan 1, 2017
Apollo Therapeutics

Cambridge, Cambridgeshire, United Kingdom

Apollo Therapeutics is a portfolio biopharmaceutical company focused on translating medical research into medicines.

BiopharmaBiotechnologyHealth CareMedicalTherapeutics
SeedJan 1, 2017
Intract Pharma

London, England, United Kingdom

Intract Pharma is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies.

BiotechnologyLife SciencePharmaceutical
SeedJan 1, 2017
Achilles Therapeutics

London, England, United Kingdom

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

BiotechnologyHealth CareTherapeuticsWellness
SeedSep 28, 2016
Amount Raised: $17,215,632